Madhav Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 0.70 M
as on 23-10-2024
- Company Age 20 Year, 23 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.00 M
as on 23-10-2024
- Satisfied Charges ₹ 8.00 M
as on 23-10-2024
- Revenue -7.32%
(FY 2023)
- Profit -205.47%
(FY 2023)
- Ebitda -1359.06%
(FY 2023)
- Net Worth -0.73%
(FY 2023)
- Total Assets 6.94%
(FY 2023)
About Madhav Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.70 M.
The company currently has active open charges totaling ₹9.00 M. The company has closed loans amounting to ₹8.00 M, as per Ministry of Corporate Affairs (MCA) records.
Ashok Agarwal, Sandhya, Ashutosh Aggarwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232DL2004PTC131016
- Company No.
131016
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Dec 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- LocationNa, Delhi
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Madhav Drugs?
Board Members(4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Ashok Agarwal | Director | 07-Dec-2004 | Current |
Sandhya | Director | 07-Dec-2004 | Current |
Ashutosh Aggarwal | Additional Director | 14-Jun-2023 | Current |
Madhav Aggarwal | Director | 21-Dec-2015 | Current |
Financial Performance of Madhav Drugs.
Madhav Drugs Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 7.32% decrease. The company also saw a substantial fall in profitability, with a 205.47% decrease in profit. The company's net worth dipped by a decrease of 0.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Madhav Drugs?
In 2023, Madhav Drugs had a promoter holding of 54.29% and a public holding of 45.71%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
Lender | Amount | Status |
---|---|---|
Canara Bank Creation Date: 24 Jul 2023 | ₹9.00 M | Open |
Syndicate Bank Creation Date: 30 Jan 2014 | ₹5.00 M | Satisfied |
Canara Bank Creation Date: 23 Feb 2007 | ₹1.00 M | Satisfied |
How Many Employees Work at Madhav Drugs?
Unlock and access historical data on people associated with Madhav Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Madhav Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Madhav Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.